Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Ms. Krishnamohan joined as Chief Financial Officer and Executive Vice President of Corporate Development in April 2024. Previously served as CFO and EVP of Corporate Development at Kinnate Biopharma and as Vice President in Healthcare Investment Banking at Goldman Sachs.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Arcutis Biotherapeutics, Inc.

2022-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Arcutis Biotherapeutics, Inc.

Open Arcutis Biotherapeutics, Inc. profile →

Director at Arcutis Biotherapeutics, Inc.

2022-01-01 → End not stated

current · source reported

Observed: 2026-09-25

Arcutis Biotherape…Arcutis Biotherapeutics, Inc.Neha Krishnamohan

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingARQT DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingARTV DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:neha-krishnamohan
Record version
public-0

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ARQT DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Latigo Biotherapeutics · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Financial Officer and Chief Business Officer · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Arcutis Biotherapeutics, Inc. · Claim reviewed: May 15, 2026

  3. ARTV DEF 14A executive officers

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 15, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Artiva Biotherapeutics, Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Financial Officer and Executive Vice President of Corporate Development · Claim reviewed: May 15, 2026
    • Other Company Role: Neha Krishnamohan is also linked to Arcutis Biotherapeutics, Inc. as Board Member. · Claim reviewed: May 15, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 15, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Arcutis Biotherapeutics, Inc. · Claim reviewed: May 15, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board membership · Source reportedServes on the board of Arcutis Biotherapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Artiva Biotherapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Latigo Biotherapeutics1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer and Chief Business Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer and Executive Vice President of Corporate Development1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Other Company Role · Source reportedNeha Krishnamohan is also linked to Arcutis Biotherapeutics, Inc. as Board Member.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources4 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1787306/000178730626000028/arqt-20260421.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  4. https://www.sec.gov/Archives/edgar/data/1787306/000178730626000028/arqt-20260421.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership